Understanding Selective Downregulation of c-Myc Expression through Inhibition of General Transcription Regulators in Multiple Myeloma
Abstract
Through analysis of the chromatin and transcriptional landscape of Multiple Myeloma (MM) and other tumors, this project has endeavored to provide an explanatory mechanism for how treatment with inhibitors of chromatin regulators can selectively target oncogene transcription, and to understand how chromatin and transcription are altered to promote tumorigenesis. Here we report the discoveries that BET bromodomains are required to communicate enhancer mediated pro-inflammatory signal dependent transduction (Brown et al., 2014), that translocations of the IgH enhancer to the MYC locus in MM expose both enhancer driven and MYC/E2F driven regulatory programs to BET bromodomain inhibition (Fulciniti et al., submitted), and that master transcription factors co-operate with one another and BET bromodomains to establish oncogenic state in MM and other tumors (Lin et al., submitted). These efforts have yielded insights into the dynamic transcriptional control of oncogenic cell state, the development of novel and extendable experimental and computational approaches, and therapeutic insights into the consequences of systemic in vivo BET bromodomain inhibition.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2015
- Accession Number
- ADA620612
Entities
People
- Charles Lin
Organizations
- Dana–Farber Cancer Institute